GVD regimen: Difference between revisions
(Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}} ==Overview== {{PAGENAME}} refers to a regimen consisting of xxx used to treat xxx. ==Regimen== {{chemo|x|xx}} {{chemo|x|xx}}...") |
No edit summary |
||
| Line 2: | Line 2: | ||
{{SI}} | {{SI}} | ||
{{CMG}}; {{AE}} {{AV}} | {{CMG}}; {{AE}} {{AV}} | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of | {{PAGENAME}} refers to a regimen consisting of [[gemcitabine]], [[vinorelbine]], [[doxorubicin]] used to treat [[Hodgkin's lymphoma]].<ref name="pmid17426059">{{cite journal| author=Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K et al.| title=Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. | journal=Ann Oncol | year= 2007 | volume= 18 | issue= 6 | pages= 1071-9 | pmid=17426059 | doi=10.1093/annonc/mdm090 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17426059 }} </ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo| | {{chemo|G|Gemcitabine}} | ||
{{chemo| | {{chemo|V|Vinorelbine}} | ||
{{chemo| | {{chemo|D|Doxorubicin}} | ||
==Indications== | ==Indications== | ||
*[[Hodgkin's lymphoma]].<ref name="pmid17426059">{{cite journal| author=Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K et al.| title=Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. | journal=Ann Oncol | year= 2007 | volume= 18 | issue= 6 | pages= 1071-9 | pmid=17426059 | doi=10.1093/annonc/mdm090 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17426059 }} </ref> | |||
==References== | ==References== | ||
Latest revision as of 20:05, 26 March 2015
|
WikiDoc Resources for GVD regimen |
|
Articles |
|---|
|
Most recent articles on GVD regimen Most cited articles on GVD regimen |
|
Media |
|
Powerpoint slides on GVD regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on GVD regimen at Clinical Trials.gov Clinical Trials on GVD regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on GVD regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on GVD regimen Discussion groups on GVD regimen Patient Handouts on GVD regimen Directions to Hospitals Treating GVD regimen Risk calculators and risk factors for GVD regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for GVD regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
GVD regimen refers to a regimen consisting of gemcitabine, vinorelbine, doxorubicin used to treat Hodgkin's lymphoma.[1]
Regimen
GGemcitabine
VVinorelbine
DDoxorubicin
Indications
References
- ↑ 1.0 1.1 Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K; et al. (2007). "Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804". Ann Oncol. 18 (6): 1071–9. doi:10.1093/annonc/mdm090. PMID 17426059.